-
Mashup Score: 5Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials - 9 day(s) ago
The aim of this study was to evaluate the efficacy of LT-02, a novel modified-release phosphatidylcholine (PC) formulation, for induction and maintenance of remission in patients with mild to moderate ulcerative colitis (UC) and inadequate response to mesalamine.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 13European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis | Pfizer - 2 month(s) ago
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY ® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent. “For the 2.6 million people in Europe living with UC, the unpredictable physical, mental, and emotional impacts of the condition can be debilitating. They may cycle through several different conventional treatment options to find relief for their symptoms,” said Séverine Vermeire, MD, PhD, Professor of Medicine at KU Leuven and an investigator in the ELEVATE Registrational Program. “The approval of VELSIPITY helps bridge the gap for those with moderately to severely
Source: www.pfizer.comCategories: General Medicine News, PayerTweet-
BREAKING: We are proud to announce that the @EU_Commission has approved our new oral treatment option for patients 16 years and older with moderately to severely active #UlcerativeColitis. More here: https://t.co/MRBS4Uctc7 https://t.co/FeNgh9S40v
-
-
Mashup Score: 3Ulcerative Colitis and Colon Cancer Risk - 5 month(s) ago
Chronic inflammation and cell damage from UC can increase your cancer risk. Here’s how to protect your health.
Source: www.healthcentral.comCategories: General Medicine News, Onc News and JournalsTweet-
What Percentage of Ulcerative Colitis Patients Get Cancer? Dr. Minhhuyhen Nguyen, the director of clinical gastroenterology at Fox Chase Cancer Center, shares commentary on #UlcerativeColitis and cancer risk with @healthcentral. Read here ⬇️ https://t.co/4bwsS4cFyY
-
-
Mashup Score: 14Mirikizumab rebounds to win FDA approval as first IL-23p19 agonist for ulcerative colitis - 6 month(s) ago
The FDA has approved Eli Lilly’s Omvoh infusion injection as the “first and only” interleukin-23p19 antagonist for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release. The agency had denied Eli Lilly’s biologic license application for Omvoh (mirikizumab-mrkz) for this indication earlier this year, citing only
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
🚨BREAKING NEWS🚨 @US_FDA approved @EliLillyandCo's Omvoh infusion injection as the “first and only” interleukin-23p19 antagonist for the treatment of patients with moderately to severely active #ulcerativecolitis. Learn more at the 🔗: https://t.co/i02Dx9EsX9
-
-
Mashup Score: 0
Omvoh is an interleukin-23 antagonist.
Source: www.empr.comCategories: General Medicine News, General Journals & SocietTweet-
New ulcerative colitis treatment mirikizumab inhibits the release of pro-inflammatory cytokines and chemokines. #UlcerativeColitis https://t.co/y99VEoYCur
-
-
Mashup Score: 14Mirikizumab rebounds to win FDA approval as first IL-23p19 agonist for ulcerative colitis - 6 month(s) ago
The FDA has approved Eli Lilly’s Omvoh infusion injection as the “first and only” interleukin-23p19 antagonist for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release. The agency had denied Eli Lilly’s biologic license application for Omvoh (mirikizumab-mrkz) for this indication earlier this year, citing only
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
🚨BREAKING NEWS🚨 @US_FDA approved @EliLillyandCo's Omvoh infusion injection as the “first and only” interleukin-23p19 antagonist for the treatment of patients with moderately to severely active #ulcerativecolitis. Learn more at the 🔗: https://t.co/i02Dx9EsX9
-
-
Mashup Score: 4Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo - 7 month(s) ago
Objectives Ulcerative colitis (UC) is a chronic inflammatory disorder of unknown aetiology. Gut virome dysbiosis is fundamental in UC progression, although its role in the early phases of the disease is far from fully understood. Therefore, we sought to investigate the role of a virome-associated protein encoded by the Orthohepadnavirus genus, the hepatitis B virus X protein (HBx), in UC aetiopathogenesis. Design HBx positivity of UC patient-derived blood and gut mucosa was assessed by RT-PCR and Sanger sequencing and correlated with clinical characteristics by multivariate analysis. Transcriptomics was performed on HBx-overexpressing endoscopic biopsies from healthy donors. C57BL/6 mice underwent intramucosal injections of liposome-conjugated HBx-encoding plasmids or the control, with or without antibiotic treatment. Multidimensional flow cytometry analysis was performed on colonic samples from HBx-treated and control animals. Transepithelial electrical resistance measurement, prolife
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
RT @drRobinDud: Groundbreaking publication👇 https://t.co/nrVv6z6EFl 🫴for aetiopathogenesis & in #UlcerativeColitis 🫳therapeutic interventi…
-
-
Mashup Score: 0
The FDA has approved Pfizer’s 2 mg once-daily Velsipity, an oral, selective sphingosine-1-phosphate receptor modulator, to treat adult patients with moderately to severely active ulcerative colitis, according to a company press release. This approval designates Velsipity (etrasimod) as only the second S1P receptor modulator available for the treatment of UC since Zeposia (Ozanimod, Bristol
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from @US_FDA, @pfizer: #FDA approves #Pfizer’s #Velsipity 💊 as ‘oral, once-daily pill’ for #ulcerativecolitis https://t.co/YWtJom5soo
-
-
Mashup Score: 4
The FDA has approved Pfizer’s 2 mg once-daily Velsipity, an oral, selective sphingosine-1-phosphate receptor modulator, to treat adult patients with moderately to severely active ulcerative colitis, according to a company press release. This approval designates Velsipity (etrasimod) as only the second S1P receptor modulator available for the treatment of UC since Zeposia (Ozanimod, Bristol
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
BREAKING 🚨 @US_FDA has approved @pfizer’s 2 mg once-daily #Velsipity 💊, an oral, selective sphingosine-1-phosphate receptor modulator, to treat adult patients with moderately to severely active #ulcerativecolitis. #GITwitter Learn more at the 🔗: https://t.co/YWtJom5soo
-
-
Mashup Score: 12FDA Approves New Drug for Ulcerative Colitis - 7 month(s) ago
Etrasimod is the second oral sphingosine-1-phosphate (S1P) receptor approved in the US for treating moderate to severe active ulcerative colitis in adults.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet-
FDA approves new drug for #ulcerativecolitis https://t.co/oOvmNESi0L
-
Two double-blind, randomized, placebo-controlled trials examine modified-release phosphatidylcholine (LT-02) for #ulcerativecolitis. Read the open access article🔓🔗https://t.co/wOYi462iDu https://t.co/cHJU4b1jHu